SRR934791
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 128.15374507227332
- age_years
- 36
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.402
- MYC_TARGETS_V1+0.389
- MITOTIC_SPINDLE+0.346
- ANDROGEN_RESPONSE+0.336
- CHOLESTEROL_HOMEOSTASIS+0.331
- TGF_BETA_SIGNALING+0.325
- E2F_TARGETS+0.304
- G2M_CHECKPOINT+0.303
- NOTCH_SIGNALING+0.249
- DNA_REPAIR+0.248
Top 10 suppressed
- KRAS_SIGNALING_DN-0.416
- MYOGENESIS-0.364
- ANGIOGENESIS-0.320
- APICAL_SURFACE-0.302
- COAGULATION-0.301
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- ESTROGEN_RESPONSE_LATE-0.274
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.246
- HYPOXIA-0.229
- ALLOGRAFT_REJECTION-0.212
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934777 | — | — | 0.932 |
| 2 | EFEDAFE3-FF81-47ED-97F6-1193EA375D77 | — | — | 0.904 |
| 3 | SRR934799 | — | — | 0.901 |
| 4 | A5D67B9F-5558-48FC-81A3-642D1903DA1F | — | — | 0.897 |
| 5 | 7A392761-6834-4B60-A49A-99D0D2AEC612 | — | — | 0.895 |
| 6 | 6EE50ED0-9F0E-4393-B165-257D5C03F221 | — | — | 0.895 |
| 7 | D5E8379B-621C-4551-9B13-E63B1B068488 | — | — | 0.894 |
| 8 | 4992152D-1D3D-4156-9D80-1B6810AAE78F | — | — | 0.885 |
| 9 | E79FE058-F03E-45F3-A939-356B0427E1B7 | — | — | 0.878 |
| 10 | 68CE8E02-F24A-4580-9881-DFBB288E2ED7 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.402 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.389 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.346 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.336 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.331 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.325 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.304 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.303 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.249 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.248 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.244 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.235 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.165 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.136 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.126 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.124 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.114 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.085 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.068 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.057 | Inavolisib | — uncovered |